Cargando…

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts

OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholde...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogervorst, Milou A, Møllebæk, Mathias, Vreman, Rick A, Lu, Ting-An, Wang, Junfeng, De Bruin, Marie Louise, Leufkens, Hubert G M, Mantel-Teeuwisse, Aukje, Goettsch, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462958/
https://www.ncbi.nlm.nih.gov/pubmed/37640462
http://dx.doi.org/10.1136/bmjopen-2023-072309
_version_ 1785098147206266880
author Hogervorst, Milou A
Møllebæk, Mathias
Vreman, Rick A
Lu, Ting-An
Wang, Junfeng
De Bruin, Marie Louise
Leufkens, Hubert G M
Mantel-Teeuwisse, Aukje
Goettsch, Wim
author_facet Hogervorst, Milou A
Møllebæk, Mathias
Vreman, Rick A
Lu, Ting-An
Wang, Junfeng
De Bruin, Marie Louise
Leufkens, Hubert G M
Mantel-Teeuwisse, Aukje
Goettsch, Wim
author_sort Hogervorst, Milou A
collection PubMed
description OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholders may be achieved, and second, to determine to what extent convergence can be achieved. DESIGN: Qualitative study using eight online dual-moderator focus groups. SETTING: Discussions had a European focus and were contextualised in four case studies on head and neck cancer, diabetes mellitus, multiple sclerosis and myelodysplastic syndromes. PARTICIPANTS: Forty-two experienced (over 10 years) European regulators, HTA representatives and clinicians participated in the discussion. INTERVENTIONS: Participants received information on the case study and research topic in advance. An introductory background presentation and interview guide for the moderators were used to steer the discussion. RESULTS: Convergence may be achieved through improved communication institutionalised in multistakeholder early dialogues, shared definitions and shared methods. Required data sets should be inclusive rather than aligned. Deliberation and decision-making should remain independent. Alignment could be sought for pragmatic clinical trial designs and patient registries. Smaller and lower-income countries should be included in these efforts. CONCLUSION: Actors in the field expressed that improving synergy among stakeholders always involves trade-offs. A balance needs to be found between the convergence of processes and the institutional remits or geographical independence. A similar tension exists between the involvement of more actors, for example, patients or additional countries, and the level of collaboration that may be achieved. Communication is key to establishing this balance.
format Online
Article
Text
id pubmed-10462958
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104629582023-08-30 Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts Hogervorst, Milou A Møllebæk, Mathias Vreman, Rick A Lu, Ting-An Wang, Junfeng De Bruin, Marie Louise Leufkens, Hubert G M Mantel-Teeuwisse, Aukje Goettsch, Wim BMJ Open Health Policy OBJECTIVE: Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholders may be achieved, and second, to determine to what extent convergence can be achieved. DESIGN: Qualitative study using eight online dual-moderator focus groups. SETTING: Discussions had a European focus and were contextualised in four case studies on head and neck cancer, diabetes mellitus, multiple sclerosis and myelodysplastic syndromes. PARTICIPANTS: Forty-two experienced (over 10 years) European regulators, HTA representatives and clinicians participated in the discussion. INTERVENTIONS: Participants received information on the case study and research topic in advance. An introductory background presentation and interview guide for the moderators were used to steer the discussion. RESULTS: Convergence may be achieved through improved communication institutionalised in multistakeholder early dialogues, shared definitions and shared methods. Required data sets should be inclusive rather than aligned. Deliberation and decision-making should remain independent. Alignment could be sought for pragmatic clinical trial designs and patient registries. Smaller and lower-income countries should be included in these efforts. CONCLUSION: Actors in the field expressed that improving synergy among stakeholders always involves trade-offs. A balance needs to be found between the convergence of processes and the institutional remits or geographical independence. A similar tension exists between the involvement of more actors, for example, patients or additional countries, and the level of collaboration that may be achieved. Communication is key to establishing this balance. BMJ Publishing Group 2023-08-28 /pmc/articles/PMC10462958/ /pubmed/37640462 http://dx.doi.org/10.1136/bmjopen-2023-072309 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Policy
Hogervorst, Milou A
Møllebæk, Mathias
Vreman, Rick A
Lu, Ting-An
Wang, Junfeng
De Bruin, Marie Louise
Leufkens, Hubert G M
Mantel-Teeuwisse, Aukje
Goettsch, Wim
Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title_full Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title_fullStr Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title_full_unstemmed Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title_short Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
title_sort perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with european experts
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462958/
https://www.ncbi.nlm.nih.gov/pubmed/37640462
http://dx.doi.org/10.1136/bmjopen-2023-072309
work_keys_str_mv AT hogervorstmiloua perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT møllebækmathias perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT vremanricka perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT lutingan perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT wangjunfeng perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT debruinmarielouise perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT leufkenshubertgm perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT mantelteeuwisseaukje perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts
AT goettschwim perspectivesonhowtobuildbridgesbetweenregulationhealthtechnologyassessmentandclinicalguidelinedevelopmentaqualitativefocusgroupstudywitheuropeanexperts